Tebanicline

From Self-sufficiency
Jump to: navigation, search
Tebanicline
240px
Systematic (IUPAC) name
5-([(2R)-azetidin- 2-yl] methoxy)- 2-chloropyridine
Identifiers
CAS Number 198283-73-7
ATC code none
PubChem CID 3075702
Chemical data
Formula C9H11ClN2O
Molar mass 198.649[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Tebanicline (Ebanicline, ABT-594) is a drug developed by Abbott, which acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes.[1] It was developed as a less toxic analogue of the potent frog-derived compound epibatidine, which is some 200x stronger than morphine as an analgesic but produces extremely dangerous toxic side effects.[2][3] Like epibatidine, tebanicline showed potent analgesic activity against neuropathic pain in both animal and human trials, but with far less toxicity than its parent compound.[4][5][6][7][8][9]

Tebanicline got as far as Phase II trials in humans,[10] but was dropped from further development due to unacceptable incidence of gastrointestinal side effects.[11] However further research in this area is ongoing,[12][13][14][15] and it is expected that development of new neural nicotinic acetylcholine receptor agonists will be likely to lead to novel analgesics suitable for use in humans within the next few years.[16][17][18][19]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


Opioids
See also: Opioids template
Opium & alkaloids thereof
Semi-synthetic opium
derivatives
Synthetic opioids
Pyrazolones
Cannabinoids
Anilides
Non-steroidal
anti-inflammatories
See also: NSAIDs template
Propionic acid class
Oxicam class
Acetic acid class
Anthranilic acid
(fenamate) class
Atypical, Adjuvant & Potentiators,
Metabolic agents and miscellaneous
Acetylcholinesterases
Ampakines
CX-516 • CX-546 • CX-614 • CX-691 • CX-717 • IDRA-21 • LY-404,187 • LY-503,430 • PEPA • Sunifiram • Unifiram
D1 Agonists
Eugeroics
GABAA α5 Inverse Agonists
H3 Antagonists
mACh Agonists
nACh Agonists
Racetams
Others


40px This analgesic-related article is a stub. You can help ssf by expanding it.
es:Tebaniciclina
  1. Jump up ↑ Jain, KK (2004). "Modulators of nicotinic acetylcholine receptors as analgesics". Current opinion in investigational drugs (London, England : 2000). 5 (1): 76–81. PMID 14983978.  edit
  2. Jump up ↑ Bannon, AW; Decker, MW; Holladay, MW; Curzon, P; Donnelly-Roberts, D; Puttfarcken, PS; Bitner, RS; Diaz, A; Dickenson, AH (1998). "Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors". Science (New York, N.Y.). 279 (5347): 77–81. PMID 9417028.  edit
  3. Jump up ↑ Holladay, M.; Wasicak, J.; Lin, N.; He, Y.; Ryther, K.; Bannon, A.; Buckley, M.; Kim, D.; Decker, M. (1998). "Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors". Journal of Medicinal Chemistry. 41 (4): 407–412. doi:10.1021/jm9706224. PMID 9484491.  edit
  4. Jump up ↑ Donnelly-Roberts, DL; Puttfarcken, PS; Kuntzweiler, TA; Briggs, CA; Anderson, DJ; Campbell, JE; Piattoni-Kaplan, M; Mckenna, DG; Wasicak, JT (1998). "ABT-594 (R)-5-(2-azetidinylmethoxy)-2-chloropyridine: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization". The Journal of pharmacology and experimental therapeutics. 285 (2): 777–86. PMID 9580626.  edit
  5. Jump up ↑ Bannon, AW; Decker, MW; Curzon, P; Buckley, MJ; Kim, DJ; Radek, RJ; Lynch, JK; Wasicak, JT; Lin, NH (1998). "ABT-594 (R)-5-(2-azetidinylmethoxy)-2-chloropyridine: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization". The Journal of pharmacology and experimental therapeutics. 285 (2): 787–94. PMID 9580627.  edit
  6. Jump up ↑ Decker, MW; Bannon, AW; Buckley, MJ; Kim, DJ; Holladay, MW; Ryther, KB; Lin, NH; Wasicak, JT; Williams, M (1998). "Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice". European journal of pharmacology. 346 (1): 23–33. doi:10.1016/S0014-2999(98)00042-9. PMID 9617748.  edit
  7. Jump up ↑ Kesingland, AC; Gentry, CT; Panesar, MS; Bowes, MA; Vernier, JM; Cube, R; Walker, K; Urban, L (2000). "Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain". Pain. 86 (1-2): 113–8. doi:10.1016/S0304-3959(00)00233-5. PMID 10779668.  edit
  8. Jump up ↑ Sorbera LA, Revel L, Leeson PA, Castaner J. ABT-594. Drugs Future 2001; 26: 927-934).
  9. Jump up ↑ Lynch Jj, 3.; Wade, C.; Mikusa, J.; Decker, M.; Honore, P. (2005). "ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model". European journal of pharmacology. 509 (1): 43–48. doi:10.1016/j.ejphar.2004.12.034. PMID 15713428.  edit
  10. Jump up ↑ Decker, M.; Meyer, M.; Sullivan, J. (2001). "The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control". Expert opinion on investigational drugs. 10 (10): 1819–1830. doi:10.1517/13543784.10.10.1819. PMID 11772288.  edit
  11. Jump up ↑ Meyer MD. Neuronal Nicotinic Acetylcholine Receptors as a Target for the Treatment of Neuropathic Pain. Drug Development Research. 2006; 67: 355-359.
  12. Jump up ↑ Baraznenok, I.; Jonsson, E.; Claesson, A. (2005). "3-(2,5-Dihydro-1H-pyrrol-2-ylmethoxy)pyridines: synthesis and analgesic activity". Bioorganic & medicinal chemistry letters. 15 (6): 1637–1640. doi:10.1016/j.bmcl.2005.01.058. PMID 15745813.  edit
  13. Jump up ↑ Zhang, C.; Ge, Z.; Cheng, T.; Li, R. (2006). "Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594". Bioorganic & medicinal chemistry letters. 16 (7): 2013–2016. doi:10.1016/j.bmcl.2005.12.073. PMID 16412637.  edit
  14. Jump up ↑ Bunnelle, W.; Daanen, J.; Ryther, K.; Schrimpf, M.; Dart, M.; Gelain, A.; Meyer, M.; Frost, J.; Anderson, D. (2007). "Structure-activity studies and analgesic efficacy of N-(3-pyridinyl)-bridged bicyclic diamines, exceptionally potent agonists at nicotinic acetylcholine receptors". Journal of Medicinal Chemistry. 50 (15): 3627–3644. doi:10.1021/jm070018l. PMID 17585748.  edit
  15. Jump up ↑ Joshi, S.; Mikusa, J.; Weaver, B.; Honore, P. (2008). "Morphine and ABT-594 (a nicotinic acetylcholine agonist) exert centrally mediated antinociception in the rat cyclophosphamide cystitis model of visceral pain". The journal of pain : official journal of the American Pain Society. 9 (2): 146–156. doi:10.1016/j.jpain.2007.09.004. PMID 18088559.  edit
  16. Jump up ↑ Lloyd GK, Williams M. Neuronal Nicotinic Acetylcholine Receptors as Novel Drug Targets. Journal of Pharmacology and Experimental Therapeutics. 2000; 292:461-467.
  17. Jump up ↑ Vincler, M. (2005). "Neuronal nicotinic receptors as targets for novel analgesics". Expert opinion on investigational drugs. 14 (10): 1191–1198. doi:10.1517/13543784.14.10.1191. PMID 16185161.  edit
  18. Jump up ↑ Arneric, S.; Holladay, M.; Williams, M. (2007). "Neuronal nicotinic receptors: a perspective on two decades of drug discovery research". Biochemical pharmacology. 74 (8): 1092–1101. doi:10.1016/j.bcp.2007.06.033. PMID 17662959.  edit
  19. Jump up ↑ Wells, GB (2008). "Structural answers and persistent questions about how nicotinic receptors work". Frontiers in bioscience : a journal and virtual library. 13: 5479–510. doi:10.2741/3094. PMC 2430769 Freely accessible. PMID 18508600.  edit
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Tebanicline&oldid=23437"